Tudor Investment Corp ET AL significantly increased its stake in Regency Centers Corporation (NASDAQ:REG) by 226.6% in the third quarter, now holding 36,002 shares valued at approximately $2.63 million. This increase comes even as Chairman Martin E. Stein, Jr. sold a substantial portion of his shares. Analysts maintain a "Moderate Buy" rating for Regency Centers with a consensus target price of $80.14, and the company offers a quarterly dividend of $0.755, yielding 3.9%, despite a high payout ratio.

Robeco Institutional Asset Management has significantly increased its stake in Regeneron Pharmaceuticals Inc. by 116.6%, adding 140,966 shares to its holdings. This brings Robeco's total to 261,850 shares, valued at over $202 million, signaling strong confidence in Regeneron's innovative drug pipeline and growth prospects. The investment firm cited Regeneron's robust product portfolio and development pipeline as key drivers for this decision.

Massachusetts Financial Services Co. increased its stake in Quanta Services (NYSE:PWR) by 16.4% in the fourth quarter, now holding 961,708 shares valued at $405.9 million. This contributes to the stock's high institutional ownership of about 90.5%. Quanta Services reported strong Q4 earnings, surpassing expectations with $3.16 EPS on $7.84 billion revenue and analysts maintain a "Moderate Buy" rating with an average price target of $595.50.

This article compares American Express and Visa, two financial stocks held by Warren Buffett's Berkshire Hathaway, to determine which is the better investment. It highlights American Express's brand strength, focus on premium customers, and success in attracting younger cardholders, while emphasizing Visa's highly profitable and scalable payments infrastructure model. Despite differences in their business models and valuations, the author suggests American Express has a higher potential for better returns over the next five years.

Massachusetts Financial Services Co. MA reduced its stake in Colgate-Palmolive Company by 0.5% in the fourth quarter, selling 20,407 shares. Despite this, they still hold 4,454,045 shares valued at approximately $352 million. Colgate-Palmolive exceeded Q4 earnings expectations with $0.95 EPS and $5.23 billion in revenue, and subsequently increased its quarterly dividend to $0.53.

Astera Labs (NASDAQ: ALAB) is positioned as a key beneficiary of surging AI infrastructure spending, with analysts projecting 30-50% upside for its stock in 2026. The company provides essential high-speed connectivity solutions for AI data centers and reported strong 2025 revenue growth and optimistic 2026 guidance. While the stock trades at high multiples and faces competition, the consensus among analysts is a "buy" given its crucial role in the expanding AI ecosystem, though investors should be mindful of potential volatility and execution risks.

Massachusetts Financial Services Co. MA significantly reduced its stake in Merck & Co., Inc. (NYSE:MRK) by selling 3,132,999 shares in Q4, decreasing its holdings by 41.5%. Following this, the institutional investor now owns 4,416,021 shares valued at approximately $464.8 million. This sale comes amidst other institutional investors either raising their positions or insider selling activities, with insiders having sold a total of 320,176 shares recently.

Massachusetts Financial Services Co. MA has reduced its stake in The Sherwin-Williams Company (NYSE:SHW) by 6.7%, selling 121,047 shares, but still owning 1.68 million shares valued at approximately $543.84 million. While several analysts have recently trimmed price targets, the stock maintains a "Moderate Buy" rating with an average target of $379.77. The company increased its quarterly dividend to $0.80 per share, offering a 1.0% yield, despite recent insider share sales.

Massachusetts Financial Services Co. MA reduced its stake in CMS Energy Corporation by 6.4% in the fourth quarter, selling 570,242 shares while retaining over 8.2 million shares valued at approximately $578.5 million. Concurrently, corporate insiders sold 20,664 shares of CMS Energy stock worth $1.58 million in the last 90 days. The company recently increased its quarterly dividend to $0.57 per share and reported strong Q4 results, surpassing revenue expectations by 12.3% year-over-year.

Regeneron Pharmaceuticals (REGN) recently gained FDA approval to extend EYLEA HD dosing intervals up to 20 weeks for certain patients, which could strengthen its position in retinal care by reducing treatment burden and increasing flexibility. While this decision is positive for defending the retinal franchise against competition and complements the upcoming prefilled syringe approval, investors must still consider the ongoing risks of pricing pressure and reliance on EYLEA. Regeneron's long-term growth profile forecasts $18.7 billion in revenue and $6.0 billion in earnings by 2029, with a fair value of $873.78 implying a 17% upside.